Splenic and lung response to nonlethal systemic Aspergillus fumigatus infection in C57BL/6 mice

Medical Mycology

Volumn 48, Issue 5, 2010, Pages 735-743

  Mirkov, Ivana ^a   Stojanovic, Ivana ^a   Stosic Grujicic, Stanislava ^a   Glamoclija, Jasmina ^a   Zolotarevski, Lidija ^b   Kataranovski, Dragan ^a   Kataranovski, Milena ^a  

^a UNIVERSITY OF BELGRADE   (Serbia)

^b UNIVERSITY OF DEFENCE   (Serbia)

Author keywords

IFN ; IL 17; IL 4; Lungs; Nonlethal murine systemic aspergillosis; Spleen

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 17; INTERLEUKIN 4; MESSENGER RNA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ASPERGILLOSIS; ASPERGILLUS FUMIGATUS; CONTROLLED STUDY; CYTOKINE PRODUCTION; FEMALE; FUNGUS CULTURE; GENE EXPRESSION; LUNG; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PROTEIN EXPRESSION; SPLEEN; SPLEEN CELL; ANIMAL; BIOSYNTHESIS; C57BL MOUSE; GENE EXPRESSION PROFILING; HUMAN; IMMUNOLOGY; ISOLATION AND PURIFICATION; MICROBIOLOGY; PATHOLOGY; TIME;

ASPERGILLUS FUMIGATUS; MURINAE; MUS;

ANIMALS; ASPERGILLOSIS; ASPERGILLUS FUMIGATUS; FEMALE; GENE EXPRESSION PROFILING; HUMANS; INTERFERON-GAMMA; INTERLEUKIN-17; INTERLEUKIN-4; LUNG; MICE; MICE, INBRED C57BL; SPLEEN; TIME FACTORS;

EID: 77954804068     PISSN: 13693786     EISSN: 14602709     Source Type: Journal    
DOI: 10.3109/13693780903496591     Document Type: Article

References (36)

1. Latge JP. Aspergillus fumigatus and aspergillosis. Clin Microbiol Rev 1999; 12: 310-350.
2. Mullins J, Hutcheson PS, Slavin RG. Aspergillus fumigatus spore concentration in outside air: Cardiff and St. Luis compared. Clin Allergy 1984; 14: 351-354.
3. Nolard N. Les liens entre les risques d'aspergillose et la contamination de l'environnement. Revue de la litterature. Pathol Biol 1994; 42: 706-710.
4. Goodley JM, Clayton YM, Hay RJ. Environmental sampling for aspergilli during building construction on a hospital site. J Hosp Infect 1994; 26: 27-35.
5. Hospenthal DR, Kwon-Chung KJ, Bennett JE. Concentrations of airborne Aspergillus compared to the incidence of invasive aspergillosis: lack of correlation. Med Mycol 1998; 36: 165-168.
6. Romani L. Immunity to fungal infections. Nat Rev Immunol 2004; 4: 1-23.
7. Clemons KV, Stevens DA. The contribution of animal models of aspergillosis to understanding pathogenesis, therapy and virulence. Med Mycol 2005; 43: S101-S110.
8. Cenci E, Mencacci A, d'Ostiani CF, et al. Cytokine-and T helperdependent lung mucosal immunity in mice with invasive pulmonary aspergillosis. J Infect Dis 1998; 178: 1750-1760.
9. Centeno-Lima S, Silveira H, Casimiro C, Aguiar P, do Rosario VE. Kinetics of cytokine expression in mice with invasive aspergillosis: lethal infection and protection. FEMS Immunol Med Microbiol 2002; 32: 167-173.
10. Schmidt A. Animal models of aspergillosis - also useful for vaccination strategies? Mycoses 2002; 45: 38-40.
11. Polak A. Experimental models in antifungal chemotherapy. Mycoses 1998; 41: 1-30.
12. Mirkov I, Zolotarevski L, Glamoclija J, Kataranovski D, Kataranovski M. Experimental disseminated aspergillosis in mice: histopathological study. J Med Mycol 2008; 18: 75-82.
13. Cenci E, Perito S, Enssle KH, et al. Th1 and Th2 cytokines in mice with invasive aspergillosis. Infect Immun 1997; 65: 564-570.
14. Nagai H, Guo J, Choi HY, Kurup V. Interferon-γ and tumor necrosis factor-αprotect mice from invasive aspergillosis. J Infect Dis 1995; 172: 1554-1560.
15. Clemons KV, Grunig G, Sobel RA, et al. Role of IL-10 in invasive aspergillosis: increased resistance of IL-10 gene knockout mice to lethal systemic aspergillosis. Clin Exp Immunol 2000; 122: 186-191.
16. Palm NW, Medzhitov R. Antifungal defense turns 17. Nat Immunol 2007; 8: 549-551.
17. Zelante T, De Luca A, D'Angelo C, Moretti S, Romani L. IL-17/ Th17 in anti-fungal immunity: what's new? Eur J Immunol 2009; 39: 645-648.
18. Zelante T, De Luca A, Bonifazi P, et al. IL-23 and the Th17 pathway promote infl ammation and impair antifungal immune resistance. Eur J Immunol 2007; 37: 2695-2706.
19. Zelante T, Bozza S, De Luca A, et al. Th17 cells in the setting of Aspergillus infection and pathology. Med Mycol 2009; 47: S162-S169.
20. Booth C. Fungal culture media. In: Norris JR, Ribbons DW (eds). Methods in Microbiology, 4th edn. London & New York: Academic Press, 1971: 49-94.
21. Sheppard DC, Marr KA, Fredricks DN, et al. Comparison of three methodologies for the determination of pulmonary fungal burden in experimental murine aspergillosis. Clin Microbiol Infect 2006; 12: 376-380.
22. Monboisse JC, Garnotel R, Randoux A, Dufer J, Borel JP. Adhesion of human neutrophils to and activation by type-I collagen involving a β2 integrin. J Leukoc Biol 1991; 50: 373-380.
23. Mebius RE, Kraal G. Structure and function of the spleen. Nat Rev Immunol 2005; 5: 606-616.
24. Weaver CT, Hatton RD, Mangan PR, Harrington LE. IL-17 family of cytokines and the expanding diversity of effector T cell lineages. Annu Rev Immunol 2007; 25: 821-852.
25. Kleinschek MA, Muller U, Brodie S, et al. IL-23 enhances the infl ammatory cell response in Cryptococcus neoformans infection and induces a cytokine pattern distinct from IL-12. J Immunol 2006; 176: 1098-1106.
26. Huang W, Na L, Fidel PL, Schwarzenberger P. Requirement of interleukin-17A for systemic anti-Candida albicans host defense in mice. J Infect Dis 2004; 190: 624-631.
27. Matsuzaki G, Umemura M. Interleukin-17 as an effector molecule of innate and acquired immunity against infections. Microbiol Immunol 2007; 51: 1139-1147.
28. Nakae S, Komiyama Y, Nambu A, et al. Antigen-specific T cell sensitization is impaired in IL-17-deficient mice, causing suppression of allergic cellular and humoral responses. Immunity 2002; 17: 375-387.
29. Abbas AK, Lichtman AH, Pillai S. Cytokines. In: Schmitt W, Gruliow R (eds). Cellular and Molecular Immunology, 6th edn. Philadelphia: Saunders Elsevier, 2007: 267-303.
30. Bernhisel-Broadbent J, Camargo EE, Jaffe HS, Lederman HM. Recombinant human interferon-gamma as adjunct therapy for Aspergillus infection in a patient with chronic granulomatous disease. J Infect Dis 1991; 163: 908-911.
31. Rex JH, Bennett JE, Gallin JI, et al. In vivo interferon-therapy augments the in vitro ability of chronic granulomatous disease neutrophils to damage Aspergillus hyphae. J Infect Dis 1991; 163: 849-852.
32. Roilides E, Uhlig K, Venzon D, Pizzo PA, Walsh TJ. Enhancement of oxidative response and damage caused by human neutrophils to Aspergillus fumigatus hyphae by granulocyte colony-stimulating factor and-interferon. Infect Immun 1993; 61: 1185-1193.
33. de Repentigny L, Petitbois S, Boushira M, et al. Acquired immunity in experimental murine aspergillosis is mediated by macrophages. Infect Immun 1993; 61: 3791-3802.
34. Cenci E, Mencacci A, Del Sero G, et al. Interleukin-4 causes susceptibility to invasive pulmonary aspergillosis through suppression of protective type I responses. J Infect Dis 1999; 180: 1957-1968.
35. Rivera A, Van Epps HL, Hohl TM, Rizzuto G, Pamer EG. Distinct CD4+-T-cell responses to live and heat-inactivated Aspergillus fumigatus conidia. Infect Immun 2005; 73: 7170-7179.
36. Brieland JK, Jackson C, Menzel F, et al. Cytokine networking in lungs of immunocompetent mice in response to inhaled Aspergillus fumigatus. Infect Immun 2001; 69: 1554-1560.